menu search

POAI / Predictive Oncology has an AI-driven drug discovery platform to improve cancer treatments and speed up drug development

Predictive Oncology has an AI-driven drug discovery platform to improve cancer treatments and speed up drug development
Predictive Oncology Inc is blazing a path as a company that can operate through the fullness of the R&D spectrum of pharma and speed up new cancer treatments. The Minneapolis, Minnesota-based company shared initial results in December 2021, showing that its flagship drug discovery platform powered by both artificial intelligence (AI) and large patient datasets, can predict cancer drug responses with great accuracy. Read More
Posted: May 10 2022, 07:02
Author Name: Proactive Investors
Views: 110847

POAI News  

Predictive Oncology, Inc. (POAI) Q2 2023 Earnings Call Transcript

By Seeking Alpha
August 10, 2023

Predictive Oncology, Inc. (POAI) Q2 2023 Earnings Call Transcript

Predictive Oncology, Inc. (NASDAQ:POAI ) Q2 2023 Earnings Conference Call August 10, 2023 5:30 PM ET Company Participants Glenn Garmont - Managing Dir more_horizontal

Predictive Oncology dramatically narrows its quarterly loss in latest financial results

By Proactive Investors
August 10, 2023

Predictive Oncology dramatically narrows its quarterly loss in latest financial results

Predictive Oncology reported its second-quarter financial results after the bell Thursday, including a significantly narrower loss than the same quart more_horizontal

Predictive Oncology moves company headquarters to Pittsburgh

By Proactive Investors
July 18, 2023

Predictive Oncology moves company headquarters to Pittsburgh

Predictive Oncology Inc. (NASDAQ:POAI) announced that it has moved its corporate headquarters to its main laboratory facility in Pittsburgh, Pennsylva more_horizontal

Predictive Oncology adds biopharmaceutical CFO Andrew Einhorn to business advisory board

By Proactive Investors
June 27, 2023

Predictive Oncology adds biopharmaceutical CFO Andrew Einhorn to business advisory board

Predictive Oncology Inc. (NASDAQ:POAI) has announced the addition of biopharmaceutical finance industry veteran Andrew Einhorn to its business advisor more_horizontal

Predictive Oncology appoints Dr Bernard Harris Jr to Business Advisory Board

By Proactive Investors
June 20, 2023

Predictive Oncology appoints Dr Bernard Harris Jr to Business Advisory Board

Predictive Oncology Inc. (NASDAQ:POAI) has announced the appointment of Dr Bernard Harris Jr to its newly-formed Business Advisory Board (BAB). The more_horizontal

Predictive Oncology forges key partnerships to drive oncology drug development in 1Q

By Proactive Investors
May 16, 2023

Predictive Oncology forges key partnerships to drive oncology drug development in 1Q

Predictive Oncology has updated investors on its use of artificial intelligence (AI) and machine learning and its extensive biorepository of tumor s more_horizontal

Predictive Oncology, Inc. (POAI) Q1 2023 Earnings Conference Call Transcript

By Seeking Alpha
May 15, 2023

Predictive Oncology, Inc. (POAI) Q1 2023 Earnings Conference Call Transcript

Predictive Oncology, Inc. (NASDAQ:POAI ) Q1 2023 Earnings Conference Call May 15, 2023 5:30 PM ET Company Participants Glenn Garmont - Managing Direct more_horizontal

Predictive Oncology appoints translational research leader Christoph Reinhard to scientific advisory board

By Proactive Investors
April 4, 2023

Predictive Oncology appoints translational research leader Christoph Reinhard to scientific advisory board

Predictive Oncology Inc. (NASDAQ:POAI) announced the appointment of Dr. Christoph Reinhard to its scientific board to serve alongside other key though more_horizontal


Search within

Pages Search Results: